| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
Enprofylline is a derivative of theophylline which shares bronchodilator properties. Enprofylline is used in asthma, chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy. Long-term enprofylline administration may be associated with elevation in liver enzyme levels and unpredictable blood levels. |
| Indication |
Used in the management of symptoms of asthma. Also used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy. |
| Pharmacology |
Enprofylline is a synthetic dimethylxanthine derivative structurally related to theophylline and caffeine. It antagonizes erythrocyte phosphodiesterase, increasing cAMP activity. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Absorption |
Rapidly absorbed from the digestive tract |
| Half Life |
1.9 hours |
| Protein Binding |
49% |